Twitter Updates

    follow me on Twitter

    My Profile

    • EXPERTISE -
      Authority on regulatory aspects of communications and medical products, with particular emphasis on pre-approval communications; strategist to help pharma and biotech companies prepare best case for advisory committee approval; issues and crisis management. Frequent speaker on various aspects of same - drug development, promotion, reimbursement and new media in a highly regulated environment. Author of books, newspaper and magazine pieces related to drug marketing and promotion as well as HIV specialty pieces. And of course... blogger!

    About This Blog

    • Eye on FDA is published by Mark Senak of Fleishman-Hillard's Washington, D.C. office. The thoughts and ideas in this blog and postings are strictly my own and are not screened by my employer. Everything posted on this blog is my personal opinion and does not necessarily represent the views of Fleishman-Hillard or its clients.

    My Favorite Dogs

    • January20063_005
      Nick and Nora

    Stats

    • eXTReMe Tracker

    Eye on FDA edrugsearch blog ranking

    • Healthcare 100

    Syndication

    « GAO Issues Report on FDA Approval and Oversight of Mifeprex | Main | Should Doctors and Pharmacists Have a Moral Objection to Treatment? »

    August 19, 2008

    TrackBack

    TrackBack URL for this entry:
    http://www.typepad.com/services/trackback/6a00d83451bf5969e200e5540e068b8834

    Listed below are links to weblogs that reference Eye on FDA Opens Up YouTube Channel:

    Comments

    Rob

    Mark,
    I think it's a great idea to be a video aggregator for health related videos. I've signed up as a subscriber, and look forward to another health care companion in the "tubosphere" (is that a word yet? - if not it should be!)

    Rob
    On behalf of jnjhealth

    Jay Byrne

    Mark:

    You're certainly on the money with this counsel. Pharmaceutical companies (and in particular their legal and regulatory counsel) have been too slow to effective participation in this and related Web 2.0 spaces.

    Many continue to seek (usually without great success) direct control over their content by only allowing it to be posted on platforms they control.

    Success today is measured much more by the effective syndication of your content (especially video) than the number of hits or views on spaces you fully control. JnJ, GSK, and others creating brand-dedicated YouTube channels and posting content are good examples of baby steps into the shallow end of a vast pool of opportunity.

    With more than 11 billion videos viewed online monthly in North America alone, the real challenge will come when brand managers, regulators and their relevant counselors fully embrace the behaviors and manners in which content is consumed online today and begin to make commensurate investments.

    Verify your Comment

    Previewing your Comment

    This is only a preview. Your comment has not yet been posted.

    Working...
    Your comment could not be posted. Error type:
    Your comment has been posted. Post another comment

    The letters and numbers you entered did not match the image. Please try again.

    As a final step before posting your comment, enter the letters and numbers you see in the image below. This prevents automated programs from posting comments.

    Having trouble reading this image? View an alternate.

    Working...

    Post a comment

    Subscribe / Email Me

    Enter your email address:

    Delivered by FeedBurner

    Search

    • Google

      WWW
      eyeonfda.com

    September 2010

    Sun Mon Tue Wed Thu Fri Sat
          1 2 3 4
    5 6 7 8 9 10 11
    12 13 14 15 16 17 18
    19 20 21 22 23 24 25
    26 27 28 29 30